Abstract
Tumour growth is characterised by the formation of a fine vessel network or neovasculature which nourishes tumour cells. Two kinds of novel anti-angiogenic therapies are based on the prevention of vessels growth and on the destruction of those vessels already formed. We report here on the design and construction of a novel immunotoxin formed with the non-toxic type II ribosome-inactivating protein ebulin l and the mouse anti-human CD105 monoclonal antibody 44G4. The 44G4-ebulin immunotoxin was formed by covalent linking of both proteins with N-succinimidyl-3- (2-pyridyldithio)propionate (SPDP) and was purified by chromatography on Superdex 200 HiLoad. The analysis of the anti-ribosomal effects in a cell-free translation system indicated that conjugation does not affect the activity of ebulin l. The immunotoxin displays cytotoxicity with nanomolar IC50 values on human CD105+ cells like the mouse fibroblasts L929 cells transfected with the short form of human CD105 and the rat myoblasts L6E9 transfected with the long form of human CD105. In contrast, cells lacking human CD105 were 2-2.5 logs less sensitive to the immunotoxin. Free ebulin displays IC50 values in the range 10-6 M. Since CD105 is being considered as a potential target for the anti-vascular therapy of tumours, the present immunotoxin could be a promising tool for the anticancer therapy, especially due to the very low in vivo toxicity of ebulin l as compared ricin and other toxins used for immunotoxins.
Keywords: ebulin l, endoglin, cd105, anti-endoglin antibody, l929 cells, l6e9 cells, cancer therapy, anti-tumour therapy
Medicinal Chemistry
Title: Cytotoxicity of an Ebulin l-Anti-Human CD105 Immunotoxin on Mouse Fibroblasts (L929) and Rat Myoblasts (L6E9) Cells Expressing Human CD105
Volume: 1 Issue: 1
Author(s): Jorge Benitez, J. Miguel Ferreras, Raquel Munoz, Yolanda Arias, Rosario Iglesias, Manuel Cordoba-Diaz, Rosario del Villar and Tomas Girbes
Affiliation:
Keywords: ebulin l, endoglin, cd105, anti-endoglin antibody, l929 cells, l6e9 cells, cancer therapy, anti-tumour therapy
Abstract: Tumour growth is characterised by the formation of a fine vessel network or neovasculature which nourishes tumour cells. Two kinds of novel anti-angiogenic therapies are based on the prevention of vessels growth and on the destruction of those vessels already formed. We report here on the design and construction of a novel immunotoxin formed with the non-toxic type II ribosome-inactivating protein ebulin l and the mouse anti-human CD105 monoclonal antibody 44G4. The 44G4-ebulin immunotoxin was formed by covalent linking of both proteins with N-succinimidyl-3- (2-pyridyldithio)propionate (SPDP) and was purified by chromatography on Superdex 200 HiLoad. The analysis of the anti-ribosomal effects in a cell-free translation system indicated that conjugation does not affect the activity of ebulin l. The immunotoxin displays cytotoxicity with nanomolar IC50 values on human CD105+ cells like the mouse fibroblasts L929 cells transfected with the short form of human CD105 and the rat myoblasts L6E9 transfected with the long form of human CD105. In contrast, cells lacking human CD105 were 2-2.5 logs less sensitive to the immunotoxin. Free ebulin displays IC50 values in the range 10-6 M. Since CD105 is being considered as a potential target for the anti-vascular therapy of tumours, the present immunotoxin could be a promising tool for the anticancer therapy, especially due to the very low in vivo toxicity of ebulin l as compared ricin and other toxins used for immunotoxins.
Export Options
About this article
Cite this article as:
Benitez Jorge, Ferreras Miguel J., Munoz Raquel, Arias Yolanda, Iglesias Rosario, Cordoba-Diaz Manuel, Villar del Rosario and Girbes Tomas, Cytotoxicity of an Ebulin l-Anti-Human CD105 Immunotoxin on Mouse Fibroblasts (L929) and Rat Myoblasts (L6E9) Cells Expressing Human CD105, Medicinal Chemistry 2005; 1 (1) . https://dx.doi.org/10.2174/1573406053402479
DOI https://dx.doi.org/10.2174/1573406053402479 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?
Anti-Cancer Agents in Medicinal Chemistry Unveiling the Transient Protein-Protein Interactions that Modulate the Activity of Estrogen Receptor(ER)-α by Human Lemur Tyrosine Kinase-3 (LMTK3) Domain: An In Silico Study
Current Proteomics Cross-Talk between Oxidative Stress and Pro-Inflammatory Cytokines in Acute Pancreatitis: A Key Role for Protein Phosphatases
Current Pharmaceutical Design Nanocarriers for Gene Delivery - Polymer Structure, Targeting Ligands and Controlled-Release Devices
Current Nanoscience Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Optimized Methods for In Vitro and In Vivo Anti-Inflammatory Assays and Its Applications in Herbal and Synthetic Drug Analysis
Mini-Reviews in Medicinal Chemistry Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma
Current Cancer Drug Targets Loss of the Tumor Suppressor HACE1 Contributes to Cancer Progression
Current Drug Targets Patent Selections
Recent Patents on DNA & Gene Sequences Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC)
Reviews on Recent Clinical Trials Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry Software Analysis of Two-Dimensional Electrophoretic Gels in Proteomic Experiments
Current Bioinformatics Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment
Current Pharmaceutical Design CD147: A Novel Modulator of Inflammatory and Immune Disorders
Current Medicinal Chemistry Application of Hyperthermia for Cancer Treatment: Recent Patents Review
Recent Patents on Anti-Cancer Drug Discovery Subject Index To Volume 2
Current Bioactive Compounds Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials